ANTIFUNGAL ACTIVITY OF A NEW BENZOTHIAZOLE DERIVATIVE AGAINST CANDIDAIN-VITRO AND IN-VIVO

The antifungal activity of 6-amino-2-n-pentylthiobenzothiazole (APB) a gainst 26 strains of the genus Candida in vitro was studied. Susceptib ility of 17 strains was IC50 less than or equal to 40 mu mol/ml, of 7 strains IC50 = 40-80 mu mol/ml and of 2 strains IC50 80-200 mu mol/ml. Generalized candidosis of mice was treated with APB (doses 50, 100, 2 50 mg/kg) and ketoconazole (KET, 50 mg/kg of body weight). The optimal dose of APB was shown to be 100 mg/kg; 25% of mice survived after 14 days as compared to control animals. C. albicans was not found in the kidney of the sacrificed mice. 80% of mice survived after KET therapy. However, C. albicans was present in the kidney in an amount of 10(5)- 10(6) CFU/g of tissue. C. albicans did not reappear in the kidney 7 da ys after the discontinuation of APB treatment, but it was found there after KET therapy.